ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Initiation of a global consortium to study the progression of age-related macular degeneration: RIMR AMD consortium report # 1.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the design and organizational structure of a global collaborative consortium aimed at aggregating longitudinal multimodal imaging data to better understand the progression of age-related macular degeneration (AMD) and facilitate therapeutic development.
methodsThe Ryan Initiative for Macular Research (RIMR) AMD Consortium was established as a nonprofit organization, bringing together academic institutions, biopharmaceutical companies, and imaging technology providers. The consortium collects, de-identifies, and harmonizes longitudinal optical coherence tomography (OCT) data, as well as associated clinical metadata, from multiple international clinical centers using a cloud-based infrastructure. Imaging data is converted and stored in DICOM format, and associated clinical data is mapped to the OMOP Common Data Model. All analyses are conducted within a secure cloud environment, supporting both built-in and member-contributed artificial intelligence (AI) tools.
resultsAs of the time of reporting, the Consortium has ingested over 100,000 OCT volumes from more than 5,000 subjects across 7 global cohorts spanning 4 continents and 3 major OCT platforms. Based on information provided by the data providers, the dataset encompasses a wide range of AMD stages, from normal aging to late-stage neovascular or atrophic AMD, with longitudinal follow-up extending beyond 15 years for some subjects. A data harmonization pipeline has been established to convert all ingested OCT data to the DICOM standard and is thus ready for automated analysis to gain disease-related insights.
conclusionsThe RIMR AMD Consortium represents a novel model for global collaboration in AMD research, enabling the pooling and analysis of heterogeneous imaging data while addressing privacy, regulatory, and interoperability challenges. This framework may serve as a model for similar initiatives in other ocular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.